Healthy
Conditions
Brief summary
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
Interventions
Sponsors
Lexicon Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult subjects ≥18 to ≤55 years of age * Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm * Body mass index (BMI) ≥18 and ≤35 kg/sq m * Able and willing to provide written informed consent * Nonsmoker and has not used any tobacco products for at least 3 months prior to Screening * Willing to adhere to the prohibitions and restrictions specified in this protocol * Able to tolerate prolonged periods of quiet, motionless, supervised rest
Exclusion criteria
* Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing * Use of any investigational agent or study treatment within 30 days prior to Screening * Use of any protein or antibody-based therapeutic agents within 3 months prior to Screening * Prior exposure to LX4211 * Daily use of cigarettes or any tobacco products within 3 months prior to Screening and while participating in the study * History of any major surgery within 6 months prior to Screening * History of any serious adverse reaction or hypersensitivity to any inactive component of LX4211 * History of renal disease or significantly abnormal kidney function tests * History of hepatic disease or significantly abnormal liver function tests * Women who are breastfeeding or are planning to become pregnant during the study * History of any active infection within 14 days prior to Screening * History of alcohol or substance abuse within 2 years prior to Screening * History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2 * Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF \>450 msec for females and QTcF \>430 msec for males) at Screening * \>30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of Period 1 * History of additional risk factors for the presence of a family history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young age (\<=40 years), drowning or sudden infant death syndrome in a first degree relative (ie, biological parent, sibling, or child) * Any skin condition likely to interfere with ECG electrode placement or adhesion * Any skin condition likely to interfere with ECG electrode placement or adhesion * Donation or loss of \>400 mL of blood or blood product within 3 months prior to Screening * Positive urine glucose during Screening * Positive pregnancy test during Screening * Positive urine screen for drugs of abuse during Screening * Positive urine test for alcohol during Screening * Inability or difficulty swallowing whole tablets or capsules * Unable or unwilling to communicate or cooperate with the Investigator for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in QTc intervals | Day -1, Day 1 of each period (2, 3, 4) |
Secondary
| Measure | Time frame |
|---|---|
| Number of subjects experiencing an adverse event | up to 87 days |
| Plasma concentrations of LX4211 | Day 1 of each Period: predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing time on Day 1 hours |
Countries
United States
Outcome results
None listed